Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 PneumoniaArticle Published on 2022-10-012022-11-16 Journal: Lung [Category] COVID19(2023년), SARS, 변종, [키워드] adult subject ambient animal model ARDS better respiratory function blood gas analysis Comorbidities consolidation COVID-19 Delta described evidence of explain hospital Hospitalization Immunity in vitro Infection Inpatient Italy less Lineage Lower lower mortality lower risk lung parenchyma observation omicron other variant Pneumonia preliminary finding replication capacity respiratory airway Respiratory failure SARS-CoV-2 severe respiratory failure Turin variants of concern virulence wild type [DOI] 10.1007/s00408-022-00566-7 PMC 바로가기
COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysisResearch article Published on 2022-10-012022-10-05 Journal: Seminars in arthritis and rheumatism [Category] 변종, [키워드] 1:1 Acute kidney injury acute respiratory distress adjust African American AKI Analysis ARDS association Black race Cancer patients cohort analysis confounders Control controls COVID-19 database dermatomyositis determine develop Disease activity drug Gender General population glucocorticoid heterogeneous nature High dose higher odd hospitalisation ICU admission identify ILD Immunosuppressant immunosuppressive individual Infection Interstitial lung disease lower risk male mechanical ventilation Mortality neoplasm Neoplasms outcome outcomes Patient patients with COVID-19 Precaution receiving renal replacement therapy required retrieved retrospective data rheumatic disease risk RRT score Sepsis severe COVID-19 Severe COVID-19 Infection severity of COVID-19 stroke subgroup analysis syndrome therapy Treatment Venous Thromboembolism VTE was used with COVID-19 [DOI] 10.1016/j.semarthrit.2022.152034 [Article Type] Research article
Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variantsArticle Published on 2022-09-292022-11-16 Journal: Nature Communications [Category] SARS, 변종, [키워드] 95% CI Contact Contact tracing Critical Delta delta variant groups growth household contact household transmission Immune escape Increased independent Infection lower risk omicron public health risk SAR SARS-CoV-2 secondary attack rate Spread susceptibility the epidemic the mean the SARS-CoV-2 Transmissibility understanding vaccination variant variants [DOI] 10.1038/s41467-022-33233-9 PMC 바로가기
SARS-CoV-2 infection among employees working from home and on site: An occupational study in SwitzerlandArticle Published on 2022-09-162022-11-15 Journal: Frontiers in Public Health [Category] SARS, 진단, [키워드] 95% CI adjusted age anti-SARS-CoV-2 IgG antibody association Blood children collected conducted consequence Corona COVID-19 COVID-19 pandemic Employees Health higher odd household size infected with SARS-CoV-2 Infection investigated lower risk measure Measures mitigate Nestlé occupational health odds of infection participant SARS-COV-2 infection SARS-CoV-2 infection (COVID-19) Spread Switzerland the disease work from home Workplace [DOI] 10.3389/fpubh.2022.980482 PMC 바로가기
Efficacy of pharmacological interventions in COVID-19: A network meta-analysisCovid-19의 약리학 적 개입의 효능 : 네트워크 메타 분석Meta-Analysis Published on 2022-09-012022-09-08 Journal: British Journal of Clinical Pharmacology [Category] meta-analysis, 임상, 치료제, [키워드] 95% confidence interval Administered analysed Clinical improvement clinical recovery Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 database Dexamethasone drug Favipiravir followed by head Head-to-head comparison Hydroxychloroquine increase interferon Intervention investigator Lopinavir Lopinavir/ritonavir lower mortality lower risk lower risk of mortality MeSH term moderate to severe Mortality Network meta-analysis Occurrence patients with moderate pharmacological intervention Quantitative analysis Randomized controlled trial reduce reduced Relative risk Remdesivir risk Ritonavir screened Serious Adverse Event Serious Adverse Events severe COVID-19 significantly Standard of care Tocilizumab was performed [DOI] 10.1111/bcp.15338 PMC 바로가기 [Article Type] Meta-Analysis
The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidenceSARS-CoV-2에 감염되거나 암에 걸린 사람에게 COVID-19가 발병할 위험: 초기 증거에 대한 체계적인 검토Review Published on 2022-09-012022-09-12 Journal: Journal of cancer policy [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition age Analysis article articles Cancer cancer type clinician Comorbidities conducted Contact COVID-19 COVID-19 incidence COVID-19 vaccine database develop Diagnosis diagnosis of COVID-19 Evidence Haematological cancer Health Service high risk Immunocompromise individuals infected with SARS-CoV-2 infection risk lower risk measure methodological limitations Neoplasms Odds ratio Patient peer-reviewed performed positive Positive test primary endpoint Protective quantitative synthesis random random effect reported risk risk of bia SARS-CoV-2 SARS-CoV-2 test Sex suggested susceptibility systematic review the Newcastle-Ottawa Scale Treatment vaccination virus while [DOI] 10.1016/j.jcpo.2022.100338 PMC 바로가기 [Article Type] Review
Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19이미 COVID-19에 걸린 사람에 대한 코로나바이러스 질병 2019(COVID-19) 예방 접종의 필요성Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI Cleveland clinic coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination Cox proportional hazard cumulative incidence demonstrated employee evaluate examined group groups Hospitalization hospitalizations Immunity incidence infected individual Infection lower risk mRNA vaccine multivariable Not demonstrated omicron Omicron variant Person positive provide receiving remained risk risk of COVID-19 SARS-CoV-2 second dose significantly lower subjects symptomatic symptomatic COVID-19 tested uninfected vaccination Vaccines variant [DOI] 10.1093/cid/ciac022 PMC 바로가기 [Article Type] Article
Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone덱사메타손을 투여한 2019 코로나바이러스 질환(COVID-19) 입원 환자에서 렘데시비르 시작의 최적 시기Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] 95% CI acute respiratory distress addition applied benefit Clinical improvement Cohort coronavirus disease COVID-19 Cox regression models cumulative Dexamethasone difference drug exposure group Follow-up group hazard ratio Hong Kong hospital Hospital stay Hospitalization Hospitalized HRs IgG antibody In-hospital death increased risk initiated Initiation Length of hospital stay lower risk Multiple outcome Patient patients with moderate positive Probability progression Remdesivir significantly shorter Survivors syndrome time time to clinical improvement. Treatment Weighting were given WHO [DOI] 10.1093/cid/ciab728 PMC 바로가기 [Article Type] Article
Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational CohortObservational Study Published on 2022-08-242022-10-04 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, [키워드] Admission anticipated baseline benefit Clinical outcome Clinical practice Comparative comparative effectiveness research complement coronavirus disease COVID-19 Cox proportional hazard discharged Effectiveness examined excluded hazard ratio Hospital admission Hospitalization hospitalized COVID-19 patients hospitalized patient initiated invasive mechanical low-flow oxygen lower risk membrane Mortality outcome Oxygenation Patient patients patients died patients hospitalized patients with COVID-19 propensity score matching randomized trials RDV receiving reduction in mortality Remdesivir statistical significance supplemental oxygen Support survival treated Treatment unique Ventilation was used were used with COVID-19 [DOI] 10.1093/cid/ciab875 PMC 바로가기 [Article Type] Observational Study
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort studyResearch article Published on 2022-08-242022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] 1:1 Abstract Admission all-cause mortality analysed Antiviral Antiviral treatment authority calculated Chinese clinical benefit contraindication Control controls COVID-19 COVID-19 diagnosis Cox regression models Cycle threshold value Department diagnosis of SARS-CoV-2 Disease progression Effectiveness eligible evaluate event exclusion finding Follow-up for inclusion funding hazard ratio Hong Kong hospital hospitalised hospitalised patient HRs ICU admission IMV incidence rate Infection intensive care Invasive mechanical ventilation lower risk material Mild-to-moderate molnupiravir need for oxygen oral outcome outcomes Oxygen therapy pandemic Patient patients Primary outcome recipient Region registry renal required retrospective cohort retrospective cohort study RT-PCR SARS-CoV-2 SARS-COV-2 infection secondary outcome severe liver impairment Significant significantly shorter study period supplemental oxygen Support symptom onset therapy time translation viral burden virological outcome were excluded with COVID-19 [DOI] 10.1016/S1473-3099(22)00507-2 [Article Type] Research article